Lanean...

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Taylor, R S, Drummond, M F, Salkeld, G, Sullivan, S D
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group Ltd. 2004
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC524116/
https://ncbi.nlm.nih.gov/pubmed/15499118
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!